NASDAQ · CLDX
Healthcare · Biotechnology
$38.51
Up+$0.02 (+0.05%)
Updated Sep 16, 2026, 4:51 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CLDX closed at $38.51 after 20 trading sessions, down 7.85% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $39.00 | $39.19 | $37.74 | $38.51 | 686.39K |
| Sep 14, 2026 | $37.40 | $39.42 | $37.27 | $39.18 | 1M |
| Sep 11, 2026 | $38.39 | $38.59 | $36.84 | $36.90 | 1.03M |
| Sep 10, 2026 | $38.78 | $38.86 | $37.75 | $38.10 | 949.01K |
| Sep 9, 2026 | $38.95 | $40.035 | $38.67 | $38.78 | 588.42K |
| Sep 8, 2026 | $38.78 | $39.865 | $38.50 | $39.12 | 834.31K |
| Sep 4, 2026 | $38.96 | $39.81 | $38.902 | $39.68 | 414.53K |
| Sep 3, 2026 | $39.50 | $39.885 | $38.95 | $39.37 | 418K |
| Sep 2, 2026 | $39.43 | $40.55 | $39.01 | $39.48 | 476.59K |
| Sep 1, 2026 | $39.13 | $39.895 | $38.94 | $39.24 | 542.48K |
| Aug 31, 2026 | $38.86 | $39.84 | $38.74 | $39.63 | 696.91K |
| Aug 28, 2026 | $40.33 | $40.57 | $39.04 | $39.12 | 424.94K |
| Aug 27, 2026 | $40.44 | $40.995 | $40.02 | $40.46 | 450.01K |
| Aug 26, 2026 | $41.18 | $42.12 | $40.06 | $40.57 | 540.67K |
| Aug 25, 2026 | $41.02 | $41.9199 | $40.63 | $41.22 | 550.92K |
| Aug 24, 2026 | $40.16 | $40.98 | $39.53 | $40.57 | 416.89K |
| Aug 21, 2026 | $40.38 | $41.2399 | $40.12 | $40.38 | 837.69K |
| Aug 20, 2026 | $41.40 | $42.00 | $39.45 | $39.94 | 1M |
| Aug 19, 2026 | $42.10 | $43.20 | $41.325 | $41.70 | 1.39M |
| Aug 18, 2026 | $41.29 | $42.3601 | $41.03 | $41.79 | 998.96K |
The latest Smart Investors Daily articles mentioning CLDX.
CLDX research
Company profile and research snapshot.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | Morgan Stanley | Overweight | — |
| Aug 7, 2026 | Morgan Stanley | Overweight | — |
| Aug 7, 2026 | Barclays | Overweight | — |
| Jul 29, 2026 | Wells Fargo | Overweight | — |
| Jul 22, 2026 | Morgan Stanley | Overweight | — |
No generated briefing is available yet.
Benzinga · Sep 10, 2026
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $46 to $50.
Yahoo · Sep 8, 2026
HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET. The webcast of the presentation will be available on the “Events and Presentations” page of the “Investors” section of the Celldex Website. Replays will be available for 90 days following the event. About CelldexCelldex is pioneering new horizons in immunology to deliver
Benzinga · Aug 7, 2026
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $40 to $46.
Benzinga · Aug 7, 2026
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $53.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CLDX.
